Search Results
Your search for Blood matches 4628 pages
Showing 3701 - 3750The Quest to Optimize Personalized Therapies for Cancer
In the late 1980s, Brian J. Druker, MD, was investigating the BCR-ABL tyrosine kinase as a target for therapeutic intervention for chronic myeloid leukemia (CML) in a laboratory at Dana-Farber Cancer Institute in Boston. By 1993, Dr. Druker had moved to Oregon Health & Science University in...
Ginkgo biloba
The use of dietary supplements by patients with cancer has increased significantly over the past 2 decades despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and...
The Best of SIO
The following four abstracts, which describe findings in three clinical studies and one basic science study, were singled out as the top abstracts at this year’s International Conference of the Society for Integrative Oncology. Self-Administered Acupressure Zick S, Wyatt G, Murphy S; et al: The...
American Association for Advancement of Science Elects New Fellows
The American Association for the Advancement of Science (AAAS) has identified 388 individuals who have been named AAAS Fellows. These individuals have been recognized by their peers for their efforts to advance science or its applications. The new AAAS Fellows, whose names were published in the...
Conquer Cancer Foundation–Funded Research Identified Among Top Cancer Advances of 2013
The recently released Clinical Cancer Advances 2013: ASCO’s Annual Report on Progress Against Cancer, highlights the most impactful advances in clinical cancer research of the year, and this year’s report identifies two studies that were funded by the Conquer Cancer Foundation. Advances in Targeted ...
Treating Earlier to Avoid Progression to Multiple Myeloma
With an expanded list of drugs to treat multiple myeloma, experts are interested in whether treating precursor diseases to multiple myeloma can prevent progression to full-blown myeloma. In addition, new drugs are entering the armamentarium for treating multiple myeloma, noted Ruben Niesvizky, MD,...
Transplant Now or Later for High-Risk Aggressive Non-Hodgkin Lymphoma?
The use of high-dose chemotherapy and autologous hematopoietic blood or marrow transplantation for high-risk aggressive non-Hodgkin lymphoma has been extensively evaluated over the past few decades. This treatment was originally used only for patients with relapsed aggressive lymphoma. However, as...
Increased Ultraviolet Radiation Exposure May Protect Against HL, Particularly in Those With EBV-Positive Disease
Increased exposure to ultraviolet radiation may offer protection against Hodgkin lymphoma (HL), particularly against Epstein-Barr virus (EBV)-positive HL, according to a pooled analysis of studies involving 1,320 HL patients and 6.381 controls. “Our pooled analysis of 7,701 participants from 4...
SIDEBAR: Expect Questions From Your Patients About Hyperthermia
Most but not all cancer treatment with hyperthermia is still being done in clinical trials. The exception is using hyperthermia for superficial cancers, most commonly chest wall recurrences in the breast. Using hyperthermia for superficial cancer “is approved and reimbursable by Medicare,” Mark W....
Oncology Meetings
January 2014 2014 Gastrointestinal Cancers SymposiumJanuary 16-18 • San Francisco, CaliforniaFor more information: www.gicasym.org 10th Annual Clinical Breakthroughs and Challenges in Hematologic MalignanciesJanuary 18 • Orlando, FloridaFor more information:...
Stress and Tumor Biology: Insights Into Managing Stress to Help Improve Cancer Care
Stress is ubiquitous in our society, especially for people diagnosed with a life-threatening illness. There is a common misconception that stress is derived from a particular negative event. However, the event itself (the stressors, such as cancer diagnoses and treatment) does not causes stress....
Developing Intermediate Endpoints in Immunotherapy
“The immune system holds tremendous potential for long-term sustained antitumor activity,” said James P. Allison, PhD, Immunology Chair, The University of Texas MD Anderson Cancer Center, Houston, as he opened a panel discussion at a meeting cosponsored by the Friends of Cancer Research and the...
Activation of Innovative Lung Cancer Master Protocol Officially Announced, Enrollment to Begin in March
At a recent meeting in Washington, DC, Friends of Cancer Research and the Engelberg Center for Health Care Reform at the Brookings Institution officially announced activation of the Lung Cancer Master Protocol, a new research strategy that has the potential to hurdle or bypass known clinical trial...
Diagnosing and Treating Chronic Mucocutaneous Graft-vs-Host Disease
Chronic graft-vs-host disease is a major cause of late, nonrelapse death following allogeneic hematopoietic stem cell transplantation. In addition, chronic graft-vs-host disease results in significant functional impairment and decreased quality of life for long-term survivors of stem cell...
IOM Makes Clinical Data Available for Research
In 1979, Congress mandated that an epidemiologic study be launched to evaluate the frequency and type of adverse health conditions experienced by military personal as a result of their exposure to Agent Orange and other herbicides used during the Vietnam War. Called the Air Force Health Study...
Sorafenib in Differentiated Thyroid Carcinoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. New Indication On November 22, 2013, sorafenib (Nexavar) was...
Ongoing NCI-Funded Clinical Trials Actively Recruiting Patients With Advanced Cancer
This issue of The ASCO Post launches a Clinical Trials Resource Guide to increase awareness of NCI-funded phase I, II, and III clinical studies for your patients with advanced cancer. All of the studies are listed on the National Institutes of Health website at ClinicalTrials.gov. The clinical...
IFM 2005-02 Update Differs From CALGB 100104: Why?
The updated analysis of the Intergroupe Francophone du Myelome (IFM) 2005-02 trial in newly diagnosed multiple myeloma patients showed that lenalidomide (Revlimid) maintenance prolongs progression-free survival after stem cell transplantation, but does not improve overall survival, according to...
Who Opts for Chemoprevention?
Based on age and risk, an estimated 10 million women in the United States may be eligible for an agent aimed at preventing breast cancer, but chemoprevention is underutilized. Fewer than 5% of women at high risk who are offered tamoxifen for chemoprevention agree to take the drug, partly due to...
Mounting Success in Trials of Genetically Engineered T Cells to Treat Leukemias and Lymphomas
Reports have been trickling in from centers conducting research on the use of chimeric antigen receptor–modified T cells (CAR-T) in hematologic cancer, and the news is encouraging. When directed against CD19, such personalized therapeutic T cells are known as CTL019, and small pilot trials of this...
Risk-Based Breast Cancer Screening: Studies Suggest Alternatives to Age-Based Guidelines
Measuring certain hormone levels could help determine a woman’s risk for breast cancer and add a key factor to current risk-prediction models, according to investigators from Harvard Medical School. Their new study results were presented at the American Association for Cancer Research (AACR) Annual ...
Leukemia Pioneer John M. Goldman, DM, Dies at 75
“He gave his honours to the world again,his blessed part to heaven, and slept in peace.” —William Shakespeare, Henry VIII In 1971, John M. Goldman, DM, FRCP, FRCPath, FMedSci, began research in chronic myeloid leukemia (CML), a uniformly fatal disease at the time. Over the ensuing decades, Dr....
Oncology Meetings
FEBRUARY 25th International Congress on Anti-Cancer TreatmentFebruary 4-6 • Paris, FranceFor more information: www.icact.fr APOS 11th Annual ConferenceFebruary 13-15 • Tampa, FloridaFor more information:www.apos-society.org/apos2014/ European Society for Medical Oncology Sarcoma and GIST...
Bosutinib Shows 'Acceptable Safety' in Philadelphia Chromosome–Positive Leukemia
Bosutinib (Bosulif) demonstrated “acceptable safety with manageable toxicities” in a phase I/II study among patients with chronic-phase chronic myeloid leukemia (CML) or advanced Philadelphia chromosome–positive leukemia (accelerated-phase/blast-phase CML or acute lymphoblastic leukemia). Patients...
Expanded Options for Age and Donor Sources for Transplant
Although many oncologists consider matched sibling donors as the best source of grafts for hematopoietic cell transplantation, two separate studies presented at the recent American Society of Hematology Annual Meeting support the use of alternative donor grafts for patients with lymphoma and acute...
Role for Reduced-Intensity Conditioning Regimen in AML After Allogeneic Transplantation
Reduced-intensity conditioning and myeloablative-conditioning regimens following allogeneic hematopoietic cell transplantation in children with acute myeloid leukemia (AML) resulted in comparable survival, according to a study published in Blood. The study evaluated 181 patients, 39 treated with...
Leukemia/Lymphoma Pioneer Geoffrey P. Herzig, MD, Dies
Many of the advances that have bettered mankind are attributed to those who were driven by a primary passion. Geoffrey P. Herzig, MD, lived the better part of his life with a primary passion: conducting research to increase the cure rate of leukemia and lymphoma patients. His friend and colleague,...
Pomalidomide Plus Low-Dose Dexamethasone: Important New Option in Relapsed/Refractory Multiple Myeloma
Pomalidomide (Pomalyst) plus low-dose dexamethasone significantly improved progression-free survival compared to pomalidomide alone in patients with relapsed and refractory multiple myeloma enrolled in a multicenter, open-label study, the phase II part of the MM-002 trial. The study confirmed the...
In CLL With Coexisting Conditions, Chlorambucil Produces Better Outcomes With Obinutuzumab Than With Rituximab
A randomized phase III trial conducted in 26 countries found that combining chlorambucil (Leukeran) with an anti-CD20 antibody—either obinutuzumab (Gazya) or rituximab (Rituxan)—produced better outcomes among patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting...
2014 Oncology Meetings
FEBRUARY European Society for Medical Oncology Sarcoma and GIST 2014February 18-19 • Milan, ItalyFor more information: www.esmo.org 2014 BMT Tandem MeetingAmerican Society for Blood and Marrow TransplantationFebruary 19 - 23 • Orlando, FloridaFor more information: www.asbmt.org Multidisciplinary...
Ongoing NCI-Funded Clinical Trials Actively Recruiting Patients With Hematologic Cancers: Multiple Myeloma
Study Type: Non-Randomized Phase I/Interventional Study Title: Multicenter Phase I Study of Th1/Tc1 Immunotherapy Following Autologous Hematopoietic Progenitor Cell Transplantation in High-Risk Multiple Myeloma Study Sponsor and Collaborators: National Cancer Institute; Hackensack University...
City of Hope Receives $10 Million Gift to Launch Lymphoma Research and Treatment Center
A $10 million gift from Internet publishing entrepreneurs and philanthropists Emmet and Toni Stephenson and their daughter Tessa Stephenson Brand will fund the creation of the Toni Stephenson Lymphoma Center at City of Hope, Duarte, California, the cornerstone of the institution’s new Hematologic...
Impact of Comprehensive Lifestyle Change on Telomere Length and Telomerase Activity in Men With Low-Risk Prostate Cancer
Ornish et al at the University of California in San Francisco and the Preventive Medicine Research Institute in Sausalito, California, performed a 5-year study1 including 35 men on active surveillance (10 in a lifestyle-intervention group and 25 in a control group) with low-risk prostate cancer....
Long-Term Follow-up Indicates Increased Telomere Length With Lifestyle Change in Men With Low-Risk Prostate Cancer
Short telomere length in peripheral blood mononuclear cells is associated with aging and age-related diseases such as cancer, stroke, vascular dementia, cardiovascular disease, obesity, osteoporosis, and diabetes. Telomere attrition is considered a potential mechanism in triggering the chromosomal...
Novel Agents Show Activity in Non-Hodgkin Lymphoma
PI3K-mediated activation of downstream effectors allows tumors to escape from negative growth control, and this action may be checked with PI3K inhibitors. At the 2013 American Society of Hematology (ASH) Annual Meeting, researchers reported results in patients with relapsed or refractory lymphoma...
Postmastectomy Pain Effectively Treated With a Simple Injection
For postmastectomy neuropathic pain, perineural infiltration with a combination of bupivacaine and dexamethasone is a “simple, effective, practice-changing treatment that any surgeon can do,” according to Laura J. Esserman, MD, MBA, Professor of Surgery and Radiology at the University of...
FDA Approves CliniMACS CD34 Reagent System for the Prevention of Graft-vs-Host Disease in AML
The U.S. Food and Drug Administration (FDA) has approved the Miltenyi Biotec’s CliniMACS CD34 Reagent System as a Humanitarian Use Device for the prevention of graft-vs-host disease in patients with acute myeloid leukemia (AML) in first complete remission undergoing allogeneic stem cell...
ASCO's Education and Professional Development Services
Last September, Jamie H. Von Roenn, MD, left her position as Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago to join ASCO as its Senior Director of Education, Science and Professional Development. In her new position, Dr. Von Roenn will provide strategic...
Overdiagnosis of Breast Cancer: New Research Directions
Currently, one of the most challenging problems in oncology is to accurately predict whether neoplastic lesions detected by screening tests will progress. The focus on developing ever-more sensitive cancer screening tests has produced the clinical dilemma of overdiagnosis. Overdiagnosis occurs when ...
2014 Oncology Meetings
MARCH 31st Annual Miami Breast Cancer Conference®March 6-9 • Miami Beach, FloridaFor more information: www.gotoper.com/conferences/mbcc/meetings/31st-Annual-Miami-Breast-Cancer-Conference Hematology and Medical Oncology Board Review: Contemporary Practice from Memorial Sloan-Kettering Cancer...
Encouraging Early Results With Novel Agents in CLL
Two novel agents have shown promising activity in chronic lymphocytic leukemia (CLL), including poor-risk patients: the Bcl-2 inhibitor ABT-199 and the small-molecule PI3K inhibitor IPI-145. Both drugs achieved excellent response rates in heavily pretreated relapsed/refractory patients including...
First-Line Obinutuzumab/Chlorambucil Improves Outcomes Over Rituximab/Chlorambucil in Older CLL Patients With Comorbidities
Obinutuzumab (Gazyva) plus chloramubucil outperformed rituximab (Rituxan) plus chlorambucil (Leukeran) as first-line therapy in older patients with chronic lymphocytic leukemia (CLL) and comorbidities in the large CLL 11 trial. Final results showed that obinutuzumab/chloramubucil improved overall...
Haploidentical Stem Cell Transplantation Producing Good Outcomes, Expanding Transplant Pool
HLA-haploidentical hematopoietic stem cell transplantation can be performed safely, yield good outcomes, and greatly expand the number of patients with hematologic malignancies who can be treated with stem cell transplant, studies presented at the 2013 American Society of Hematology (ASH) Annual...
Amplifying the Signal: Foundation Donor Takes His Advocacy Into the Twittersphere
Michael A. Thompson, MD, PhD, a Medical Oncologist for Aurora Cancer Care and the Medical Director of Early Cancer Research at Aurora Health Care in Wisconsin, has become something of an expert on the Conquer Cancer Foundation. It began in 2006, when he received a Conquer Cancer Foundation of ASCO...
GI Symposium Presentations Include Important Updates in Treatment and Prognosis of Pancreatic and Colorectal Cancers
More than 650 studies were presented at the 2014 Gastrointestinal Cancers Symposium, which attracted a multidisciplinary group of more than 3,500 medical, surgical, and radiation oncologists and gastroenterologists. The following briefs highlight a handful of noteworthy studies from the meeting....
Ongoing Clinical Trials Actively Recruiting Patients With Gastrointestinal Cancers
This Clinical Trials Resource Guide is meant to increase awareness of currently recruiting NCI- or academic institution–sponsored clinical studies for your patients with gastrointestinal cancers. All of the studies are listed on the National Institutes of Health website at ClinicalTrials.gov, and...
2014 Oncology Meetings
MARCH Society of Surgical Oncology Annual Cancer Symposium March 13 - 16 • Phoenix, ArizonaFor more information: www.surgonc.org 24th Annual Interdisciplinary Breast Cancer ConferenceMarch 15-19 • Las Vegas, NevadaFor more information: www.breastcare.org/ 9th European Breast Cancer ConferenceMarch ...
How to Approach the Problem of CNS Metastasis in HER2-Positive Patients
Central nervous system (CNS) metastasis is a pervasive problem in the setting of HER2-positive breast cancer. While some patients can be managed easily, others are challenging, said Eric P. Winer, MD, Chief of the Division of Women’s Cancers and the Thompson Senior Investigator for Breast Cancer...
The Ketogenic Diet in Cancer Control
Ketogenic (or very-low-carbohydrate) diets have been employed since the 1920s as nonpharmacologic therapies for epilepsy and, in some instances, have obviated the need for medication for that disease. Since the 1960s, the ketogenic diet has become better known as a means of managing obesity. This...
How Decoding the Genomes of Exceptional Responders Is Leading to More Effective Treatment for All Patients With Cancer
In 2012, David B. Solit, MD, Geoffrey Beene Chair and Director of the Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, and his colleagues published the results of a phase II study1 of 45 patients with advanced bladder cancer. The purpose of the clinical...
